Selected article for: "cell transplantation and GVHD host versus graft disease"

Title: Age-related factors in cyclosporine-induced syngeneic graft-versus-host disease: regulatory role of marrow-derived T lymphocytes
  • Document date: 1990_7_1
  • ID: wmjjoyso_1
    Snippet: C yclosporine (CsA)l is a very potent immunosuppressive agent that has an apparent selective action on T lymphocyte-dependent immune responses (1, 2) . It has been used extensively in clinical transplantation to prevent solid organ allograft rejection and graft-versus-host disease (GVHD) (3, 4) . CsA is currently being evaluated as a therapeutic agent for the treatment ofautoimmune disease, and the results from these trials appear quite promising.....
    Document: C yclosporine (CsA)l is a very potent immunosuppressive agent that has an apparent selective action on T lymphocyte-dependent immune responses (1, 2) . It has been used extensively in clinical transplantation to prevent solid organ allograft rejection and graft-versus-host disease (GVHD) (3, 4) . CsA is currently being evaluated as a therapeutic agent for the treatment ofautoimmune disease, and the results from these trials appear quite promising (5) . Despite its potent immunosuppressive activity, CsA therapy after autologous or syngeneic bone marrow transplantation paradoxically elicits a T cell-mediated autoimmune syndrome with pathology identical to GVHD occurring after allogeneic bone marrow transplantation (BMT) (6) (7) (8) (9) (10) . Hence, this CsA-induced autoimmune syndrome was originally termed syngeneic GVHD (SGVHD) (6) . The immunobiology of SGVHD is complex and is not completely understood, but it appears to be due to the uncoupling of normal immunologic homeostasis involved in self-nonself recognition (11) .

    Search related documents:
    Co phrase search for related documents
    • allogeneic bone BMT marrow transplantation and clinical transplantation: 1
    • allogeneic bone BMT marrow transplantation and GVHD host versus graft disease: 1, 2, 3, 4
    • allogeneic bone BMT marrow transplantation and host versus graft: 1, 2, 3, 4
    • allogeneic bone BMT marrow transplantation and host versus graft disease: 1, 2, 3, 4
    • allogeneic bone BMT marrow transplantation and marrow transplantation: 1, 2, 3, 4, 5, 6, 7
    • allograft rejection and clinical transplantation: 1, 2
    • allograft rejection and host versus graft: 1, 2, 3, 4, 5
    • allograft rejection and host versus graft disease: 1, 2, 3, 4, 5
    • allograft rejection and immune response: 1, 2, 3, 4, 5
    • allograft rejection and marrow transplantation: 1
    • allograft rejection and organ allograft rejection: 1, 2, 3, 4, 5, 6, 7, 8
    • autoimmune syndrome and host versus graft: 1
    • autoimmune syndrome and host versus graft disease: 1
    • autoimmune syndrome and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • autoimmune syndrome and marrow transplantation: 1, 2, 3, 4
    • BMT marrow transplantation and clinical transplantation: 1
    • BMT marrow transplantation and CsA therapy: 1, 2
    • BMT marrow transplantation and GVHD host versus graft disease: 1, 2, 3, 4, 5, 6, 7, 8
    • BMT marrow transplantation and host versus graft: 1, 2, 3, 4, 5, 6, 7, 8, 9